NZ752893A - Synthetic chimeric poxviruses - Google Patents
Synthetic chimeric poxvirusesInfo
- Publication number
- NZ752893A NZ752893A NZ752893A NZ75289317A NZ752893A NZ 752893 A NZ752893 A NZ 752893A NZ 752893 A NZ752893 A NZ 752893A NZ 75289317 A NZ75289317 A NZ 75289317A NZ 752893 A NZ752893 A NZ 752893A
- Authority
- NZ
- New Zealand
- Prior art keywords
- synthetic chimeric
- chimeric poxviruses
- poxviruses
- synthetic
- viruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416577P | 2016-11-02 | 2016-11-02 | |
| US201662434794P | 2016-12-15 | 2016-12-15 | |
| PCT/US2017/059782 WO2018085582A1 (en) | 2016-11-02 | 2017-11-02 | Synthetic chimeric poxviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ752893A true NZ752893A (en) | 2025-10-31 |
Family
ID=62075555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ752893A NZ752893A (en) | 2016-11-02 | 2017-11-02 | Synthetic chimeric poxviruses |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11345896B2 (OSRAM) |
| EP (1) | EP3535389A4 (OSRAM) |
| JP (3) | JP2019535311A (OSRAM) |
| CN (1) | CN110431228B (OSRAM) |
| AU (2) | AU2017353868C1 (OSRAM) |
| BR (1) | BR112019008781A2 (OSRAM) |
| CA (1) | CA3042694A1 (OSRAM) |
| IL (2) | IL266399B2 (OSRAM) |
| MX (1) | MX2019005102A (OSRAM) |
| NZ (1) | NZ752893A (OSRAM) |
| SG (1) | SG11201903893PA (OSRAM) |
| TW (2) | TW202528334A (OSRAM) |
| WO (1) | WO2018085582A1 (OSRAM) |
| ZA (3) | ZA201902868B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ752893A (en) | 2016-11-02 | 2025-10-31 | Tonix Pharma Ltd | Synthetic chimeric poxviruses |
| WO2018148710A1 (en) * | 2017-02-13 | 2018-08-16 | Excision Biotherapeutics, Inc. | Visualizing viral reservoirs and dissemination in vivo |
| SG11202010272PA (en) * | 2018-05-02 | 2020-11-27 | David Evans | Synthetic chimeric vaccinia virus |
| US20240024393A1 (en) * | 2019-01-25 | 2024-01-25 | Virocure, Inc. | Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus |
| US20230097513A1 (en) * | 2020-02-03 | 2023-03-30 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| CN116348135A (zh) * | 2020-02-26 | 2023-06-27 | 通尼克斯制药有限公司 | 基于重组痘病毒的抗SARS-CoV-2病毒疫苗 |
| KR20240001116A (ko) | 2021-02-02 | 2024-01-03 | 지오박스, 인크. | 백신접종 동안 t-세포 프라이밍을 증진시키는 데 사용하기 위한 바이러스 구축물 |
| WO2023168286A1 (en) | 2022-03-01 | 2023-09-07 | Tonix Pharmaceuticals Holding Corp. | Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof |
| CN117264909B (zh) * | 2023-10-25 | 2024-11-26 | 深圳湾实验室 | 反式互补缺陷猴痘病毒及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2787577A (en) | 1953-12-01 | 1957-04-02 | Lilly Co Eli | Stable smallpox vaccine |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| CA2431349A1 (en) * | 2002-06-06 | 2003-12-06 | Xiao-Dan Yao | Method of producing a recombinant virus |
| WO2005028634A2 (en) | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| WO2006022215A1 (ja) | 2004-08-23 | 2006-03-02 | The Japan Health Sciences Foundation | SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用 |
| CN101020055B (zh) | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的sars疫苗 |
| US8052968B2 (en) | 2006-10-16 | 2011-11-08 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| US8795667B2 (en) * | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2014160475A1 (en) | 2013-03-13 | 2014-10-02 | Aboody Karen S | Tropic cell based virotherapy for the treatment of cancer |
| EP2984167B1 (en) | 2013-04-10 | 2019-12-04 | Tot Shanghai Rd Center Co. Ltd. | Mutant vaccinia virus strains, uses thereof and method of producing the same |
| EP3045181B1 (en) | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| JP6788663B2 (ja) | 2015-08-11 | 2020-11-25 | カリディ・バイオセラピューティクス・インコーポレイテッドＣａｌｉｄｉ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 癌処置のための天然痘ワクチン |
| CN110022867A (zh) | 2016-09-21 | 2019-07-16 | 斯蒂芬·H·索恩 | 高迁移率族蛋白box i突变体 |
| NZ752893A (en) | 2016-11-02 | 2025-10-31 | Tonix Pharma Ltd | Synthetic chimeric poxviruses |
| ES2702618B2 (es) | 2017-09-04 | 2019-10-31 | Inst De Salud Carlos Iii | Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica. |
| CN112261951A (zh) | 2018-05-02 | 2021-01-22 | 通尼克斯制药控股有限公司 | 包含合成嵌合痘苗病毒的干细胞及其使用方法 |
| SG11202010272PA (en) | 2018-05-02 | 2020-11-27 | David Evans | Synthetic chimeric vaccinia virus |
-
2017
- 2017-11-02 NZ NZ752893A patent/NZ752893A/en unknown
- 2017-11-02 BR BR112019008781-8A patent/BR112019008781A2/pt active Search and Examination
- 2017-11-02 AU AU2017353868A patent/AU2017353868C1/en active Active
- 2017-11-02 EP EP17868045.0A patent/EP3535389A4/en active Pending
- 2017-11-02 US US15/802,189 patent/US11345896B2/en active Active
- 2017-11-02 IL IL266399A patent/IL266399B2/en unknown
- 2017-11-02 TW TW113144133A patent/TW202528334A/zh unknown
- 2017-11-02 CN CN201780078546.0A patent/CN110431228B/zh active Active
- 2017-11-02 JP JP2019545700A patent/JP2019535311A/ja active Pending
- 2017-11-02 WO PCT/US2017/059782 patent/WO2018085582A1/en not_active Ceased
- 2017-11-02 CA CA3042694A patent/CA3042694A1/en active Pending
- 2017-11-02 MX MX2019005102A patent/MX2019005102A/es unknown
- 2017-11-02 IL IL319942A patent/IL319942A/en unknown
- 2017-11-02 TW TW106137976A patent/TWI887191B/zh active
- 2017-11-02 SG SG11201903893PA patent/SG11201903893PA/en unknown
-
2019
- 2019-05-07 ZA ZA2019/02868A patent/ZA201902868B/en unknown
-
2022
- 2022-05-06 ZA ZA2022/04981A patent/ZA202204981B/en unknown
- 2022-05-27 US US17/827,320 patent/US12365879B2/en active Active
- 2022-09-02 JP JP2022140113A patent/JP2022164900A/ja not_active Withdrawn
-
2024
- 2024-02-15 AU AU2024200997A patent/AU2024200997A1/en not_active Abandoned
- 2024-05-02 ZA ZA2024/03393A patent/ZA202403393B/en unknown
- 2024-06-10 JP JP2024093677A patent/JP2024107257A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL266399A (en) | 2019-06-30 |
| ZA201902868B (en) | 2022-12-21 |
| AU2017353868A1 (en) | 2019-05-16 |
| CN110431228A (zh) | 2019-11-08 |
| MX2019005102A (es) | 2019-10-30 |
| JP2022164900A (ja) | 2022-10-27 |
| IL266399B1 (en) | 2025-05-01 |
| WO2018085582A1 (en) | 2018-05-11 |
| US11345896B2 (en) | 2022-05-31 |
| TW202528334A (zh) | 2025-07-16 |
| ZA202204981B (en) | 2024-09-25 |
| US20180251736A1 (en) | 2018-09-06 |
| AU2024200997A1 (en) | 2024-03-07 |
| TW201819400A (zh) | 2018-06-01 |
| CA3042694A1 (en) | 2018-05-11 |
| TWI887191B (zh) | 2025-06-21 |
| AU2017353868C1 (en) | 2024-06-06 |
| IL319942A (en) | 2025-05-01 |
| JP2024107257A (ja) | 2024-08-08 |
| EP3535389A4 (en) | 2020-06-03 |
| JP2019535311A (ja) | 2019-12-12 |
| AU2017353868B2 (en) | 2024-02-29 |
| SG11201903893PA (en) | 2019-05-30 |
| BR112019008781A2 (pt) | 2019-07-16 |
| ZA202403393B (en) | 2025-08-27 |
| EP3535389A1 (en) | 2019-09-11 |
| IL266399B2 (en) | 2025-09-01 |
| US20230002741A1 (en) | 2023-01-05 |
| CN110431228B (zh) | 2024-04-02 |
| US12365879B2 (en) | 2025-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202403393B (en) | Synthetic chimeric poxviruses | |
| ZA202004557B (en) | Modulatory polynucleotides | |
| ZA201802657B (en) | Crystal forms of beta-nicotinamide mononucleotide | |
| MX2020011586A (es) | Virus vaccinia quimerico sintetico. | |
| PH12017500858A1 (en) | Mocrocyclic peptides useful as immunomodulators | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| MY191581A (en) | Anti-pd-1 antibodies | |
| MX2021001053A (es) | Vacunas contra virus de la influenza y sus usos. | |
| PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| MY191539A (en) | Streptococcal vaccine | |
| MX387421B (es) | Producción de virus en huevos aviares. | |
| ZA201701000B (en) | Attenuated bovine coronavirus and related vaccines | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| MX2018005462A (es) | Composiciones inmunogénicas de rsv quimérico y métodos de uso. | |
| EA201792512A1 (ru) | Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник | |
| IN2014CH00840A (OSRAM) | ||
| JOP20200126A1 (ar) | طرق استخدام وتركيبات تحتوي على دولاجلوتيد | |
| MX2018014955A (es) | Vacunas atenuadas vivas del virus de la influenza equina. | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
| MX2022010827A (es) | Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados. | |
| NZ721832A (en) | Solid forms of tenofovir | |
| MX2018005134A (es) | Formulacion de factor viii (fviii). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: TONIX PHARMA LIMITED, IE Effective date: 20250416 |